{"id":341313,"date":"2025-08-20T14:36:46","date_gmt":"2025-08-20T14:36:46","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-gsk\/"},"modified":"2025-08-20T14:36:46","modified_gmt":"2025-08-20T14:36:46","slug":"how-to-buy-gsk","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/","title":{"rendered":"GSK plc (GSK) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; GSK plc (GSK) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-341313","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"GSK plc (GSK) Hisseleri Nas\u0131l Al\u0131n\u0131r - GSK plc (GSK) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"GSK plc (GSK) Hisseleri Nas\u0131l Al\u0131n\u0131r - GSK plc (GSK) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"GSK plc (GSK) hisselerini nas\u0131l alaca\u011f\u0131n\u0131z\u0131 kapsaml\u0131 yat\u0131r\u0131m analizimizle \u00f6\u011frenin. Mevcut hisse performans\u0131n\u0131, riskleri ve 2025-2030 i\u00e7in b\u00fcy\u00fcme potansiyelini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"GSK plc (GSK) hisselerini nas\u0131l alaca\u011f\u0131n\u0131z\u0131 kapsaml\u0131 yat\u0131r\u0131m analizimizle \u00f6\u011frenin. Mevcut hisse performans\u0131n\u0131, riskleri ve 2025-2030 i\u00e7in b\u00fcy\u00fcme potansiyelini ke\u015ffedin."},"intro":"Portf\u00f6y\u00fcn\u00fcze bir ila\u00e7 devi eklemeyi mi d\u00fc\u015f\u00fcn\u00fcyorsunuz? GSK plc, yenilik ve istikrarl\u0131 b\u00fcy\u00fcme ile zengin bir ge\u00e7mi\u015fe sahip d\u00fcnyan\u0131n en k\u00f6kl\u00fc sa\u011fl\u0131k \u015firketlerinden biridir. Son FDA onaylar\u0131 ve g\u00fc\u00e7l\u00fc finansal performans\u0131yla, bu hisse hem istikrar hem de ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in heyecan verici y\u00fckseli\u015f potansiyeli sunuyor.","intro_source":{"label":"Intro","type":"text","formatted_value":"Portf\u00f6y\u00fcn\u00fcze bir ila\u00e7 devi eklemeyi mi d\u00fc\u015f\u00fcn\u00fcyorsunuz? GSK plc, yenilik ve istikrarl\u0131 b\u00fcy\u00fcme ile zengin bir ge\u00e7mi\u015fe sahip d\u00fcnyan\u0131n en k\u00f6kl\u00fc sa\u011fl\u0131k \u015firketlerinden biridir. Son FDA onaylar\u0131 ve g\u00fc\u00e7l\u00fc finansal performans\u0131yla, bu hisse hem istikrar hem de ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar i\u00e7in heyecan verici y\u00fckseli\u015f potansiyeli sunuyor."},"body_html":"<h2>\ud83d\udcc8 GSK Hisse Analizi: Mevcut Performans ve Gelecek G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>20 A\u011fustos 2025 itibar\u0131yla, GSK plc (GSK) NYSE'de <strong>39,07 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, 2025 boyunca m\u00fckemmel finansal sonu\u00e7lar ve stratejik sat\u0131n almalarla desteklenen \u015firketin g\u00fc\u00e7l\u00fc momentumunu yans\u0131t\u0131yor.<\/p> <p><strong>Takviminize not edin: 29 Ekim 2025<\/strong>, GSK yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in kesinlikle kritik bir tarih. \u015eirketin 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu \u00e7eyreklik a\u00e7\u0131klamalar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 GSK Hisselerini Nas\u0131l Etkiler?<\/h3> <p>Son tarihleri inceledi\u011fimizde piyasa tepkilerinde net bir desen g\u00f6r\u00fcl\u00fcyor:<\/p> <ul> <li><strong>30 Temmuz 2025<\/strong>: 2. \u00c7eyrek Kazan\u00e7lar\u0131 - EPS tahminlerini 0,11 $ a\u015farak hisse senedi sonraki ay %7,64 y\u00fckseldi<\/li> <li><strong>29 Nisan 2025<\/strong>: 1. \u00c7eyrek Kazan\u00e7lar\u0131 - Sa\u011flam performans rehberli\u011fi koruyarak kademeli fiyat art\u0131\u015f\u0131n\u0131 destekledi<\/li> <li><strong>\u015eubat 2025<\/strong>: Y\u0131ll\u0131k Sonu\u00e7lar - Genellikle y\u0131ll\u0131k performans beklentileri i\u00e7in ton belirler<\/li> <\/ul> <p>Desen a\u00e7\u0131k: pozitif kazan\u00e7 s\u00fcrprizleri an\u0131nda momentum yarat\u0131rken, beklentilerin kar\u015f\u0131lanmas\u0131 istikrarl\u0131 destek sa\u011flar. Yakla\u015fan Ekim raporu, GSK'n\u0131n y\u00fckseltilmi\u015f rehberli\u011fi g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda \u00f6zellikle \u00f6nemli olabilir.<\/p> <h3>6 Ayl\u0131k Fiyat Seyri (\u015eubat-A\u011fustos 2025)<\/h3> <p>GSK hisseleri, baz\u0131 dalgalanmalara ra\u011fmen <strong>y\u0131lba\u015f\u0131ndan bu yana %15,46 kazan\u00e7<\/strong> g\u00f6stererek dikkat \u00e7ekici bir diren\u00e7 sergiledi:<\/p> <ul> <li><strong>\u015eubat 2025<\/strong>: 33,80 $ (tatil sonras\u0131 konsolidasyon)<\/li> <li><strong>Nisan 2025<\/strong>: 36,20 $ (1. \u00e7eyrek kazan\u00e7 g\u00fcc\u00fc)<\/li> <li><strong>Haziran 2025<\/strong>: 38,40 $ (sat\u0131n alma haberlerinin momentumu)<\/li> <li><strong>A\u011fustos 2025<\/strong>: 39,07 $ (mevcut stabilizasyon)<\/li> <\/ul> <p>Bu y\u00fckseli\u015f e\u011filimi birka\u00e7 \u00f6nemli fakt\u00f6r\u00fc yans\u0131t\u0131yor:<\/p> <ul> <li>2025'in ilk yar\u0131s\u0131nda \u00fc\u00e7 b\u00fcy\u00fck FDA onay\u0131<\/li> <li>2 milyar dolarl\u0131k efimosfermin alfa sat\u0131n al\u0131m\u0131n\u0131n ba\u015far\u0131s\u0131<\/li> <li>\u00d6zel ila\u00e7larda \u00e7ift haneli b\u00fcy\u00fcme<\/li> <li>Arexvy liderli\u011finde g\u00fc\u00e7l\u00fc a\u015f\u0131 performans\u0131<\/li> <\/ul> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist projeksiyonlar\u0131 ve \u015firket momentumu temelinde beklenenler:<\/p> <p><strong>2025 Y\u0131l Sonu<\/strong>: Ortalama hedef 43,13 $ (%9,59 art\u0131\u015f mevcut fiyattan) ve potansiyel en y\u00fcksek 53,63 $<br\/> <strong>2026 Projeksiyonu<\/strong>: Yeni \u00fcr\u00fcnlerin piyasa \u00e7eki\u015fi kazanmas\u0131yla 46-48 $ aral\u0131\u011f\u0131nda devam eden b\u00fcy\u00fcme<br\/> <strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: Ticari ba\u015far\u0131ya ula\u015fan \u00fcr\u00fcnlerle 55-60 $ aral\u0131\u011f\u0131<br\/> <strong>2030 Vizyonu<\/strong>: Ultra uzun etkili HIV tedavileri ve di\u011fer yeniliklerin piyasalar\u0131 domine etmesiyle 65-70 $+ aral\u0131\u011f\u0131<\/p> <p><strong>Sonu\u00e7<\/strong>: G\u00dc\u00c7L\u00dc AL - Mevcut performans, \u00fcr\u00fcn hatt\u0131 g\u00fcc\u00fc ve makul de\u011ferleme kombinasyonu, GSK'y\u0131 hem k\u0131sa vadeli ticaret hem de uzun vadeli tutma i\u00e7in son derece cazip k\u0131l\u0131yor.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <p><strong>Hukuki Zorluklar<\/strong>: GSK, 2,2 milyar dolarl\u0131k Zantac uzla\u015fmas\u0131 ve Blenrep a\u00e7\u0131klamalar\u0131yla ilgili menkul k\u0131ymet doland\u0131r\u0131c\u0131l\u0131\u011f\u0131 soru\u015fturmas\u0131 dahil devam eden davalarla kar\u015f\u0131 kar\u015f\u0131ya. Bunlar k\u0131sa vadeli volatilite ve potansiyel finansal etkiler yaratabilir.<\/p> <p><strong>Reg\u00fclasyon Bask\u0131lar\u0131<\/strong>: Kanser tedavileri i\u00e7in FDA'n\u0131n g\u00f6z riskleri konusundaki endi\u015feleri ve Blenrep'in reddi, ila\u00e7 sekt\u00f6r\u00fcndeki s\u00fcrekli d\u00fczenleyici belirsizli\u011fi vurguluyor.<\/p> <p><strong>Piyasa Volatilitesi<\/strong>: \u0130\u015flem hacmi son zamanlarda %76,74 artarak 326 milyon hisseye ula\u015ft\u0131, bu da yat\u0131r\u0131mc\u0131lar\u0131n haber ak\u0131\u015f\u0131na kar\u015f\u0131 hassasiyetinin artt\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <p><strong>Finansal G\u00fc\u00e7<\/strong>: 2. \u00e7eyrek EPS 1,23 $ ile tahminleri 0,11 $ a\u015ft\u0131, gelir ise 10,64 milyar $ ile beklentileri dramatik \u015fekilde ge\u00e7ti.<\/p> <p><strong>\u00dcr\u00fcn Hatt\u0131 \u0130lerlemesi<\/strong>: Y\u0131l sonuna kadar 4'\u00fc kritik denemelere giren 16 ge\u00e7 a\u015fama varl\u0131k - bu inan\u0131lmaz bir gelecekteki gelir potansiyelini temsil ediyor.<\/p> <p><strong>Stratejik Sat\u0131n Almalar<\/strong>: Karaci\u011fer hastal\u0131\u011f\u0131 tedavisi i\u00e7in 2 milyar dolarl\u0131k efimosfermin anla\u015fmas\u0131, GSK'y\u0131 b\u00fcy\u00fcyen metabolik pazarda konumland\u0131r\u0131yor.<\/p> <p><strong>FDA Ba\u015far\u0131s\u0131<\/strong>: 2025'te \u00fc\u00e7 b\u00fcy\u00fck onay al\u0131nd\u0131, iki onay daha bekleniyor - bu y\u00fcr\u00fctme kabiliyeti etkileyici.<\/p> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <p><strong>Hemen Uygulanacak Plan<\/strong>:<\/p> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> - Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5'ini temsil eden bir pozisyonla ba\u015flay\u0131n<\/li> <li><strong>29 Ekim kazan\u00e7lar\u0131 i\u00e7in fiyat uyar\u0131lar\u0131 ayarlay\u0131n<\/strong> - %3-5'lik herhangi bir d\u00fc\u015f\u00fc\u015fte al\u0131m yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <li><strong>Dolar maliyet ortalamas\u0131 kullan\u0131n<\/strong> - giri\u015f noktalar\u0131n\u0131 yumu\u015fatmak i\u00e7in haftal\u0131k sabit miktarlarda yat\u0131r\u0131m yap\u0131n<\/li> <li><strong>Hukuki geli\u015fmeleri takip edin<\/strong> - bunlar en b\u00fcy\u00fck k\u0131sa vadeli riski temsil ediyor<\/li> <\/ol> <p><strong>Esprili t\u00fcccar bilgeli\u011fi<\/strong>: \"GSK ticareti yapmak ila\u00e7 almak gibidir - bazen a\u015fa\u011f\u0131 inerken tad\u0131 k\u00f6t\u00fc olabilir ama sabah daha iyi hissedersiniz. Panik ataklarda \u015fi\u015feyi kovalamay\u0131n!\"<\/p> <h2>\u2705 GSK plc (GSK) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NYSE eri\u015fimi ve makul komisyon oranlar\u0131 sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Genellikle kimlik ve adres kan\u0131t\u0131 gerektirir - genellikle 1-2 g\u00fcn s\u00fcrer<\/td><\/tr> <tr><td>3<\/td><td>Fon yat\u0131r\u0131n<\/td><td>Risk almaya rahat oldu\u011funuz bir miktarla ba\u015flay\u0131n - 100 $ bile yolculu\u011funuza ba\u015flaman\u0131z\u0131 sa\u011flar<\/td><\/tr> <tr><td>4<\/td><td>\"GSK\" aramas\u0131 yap\u0131n<\/td><td>Sadece \"GlaxoSmithKline\" de\u011fil, sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Piyasa emirleri yerine limit emirleri kullanarak giri\u015f fiyat\u0131n\u0131z\u0131 kontrol edin<\/td><\/tr> <tr><td>6<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>\u0130\u015flem \u00f6ncesi miktar, fiyat ve \u00fccretleri \u00e7ift kontrol edin<\/td><\/tr> <tr><td>7<\/td><td>Pozisyonunuzu izleyin<\/td><td>Riski y\u00f6netmek i\u00e7in giri\u015f fiyat\u0131n\u0131n %10-15 alt\u0131nda stop-loss ayarlay\u0131n<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, piyasaya giri\u015fin eri\u015filebilir olmas\u0131n\u0131 sa\u011flayan birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>En D\u00fc\u015f\u00fck Minimum Para Yat\u0131rma<\/strong>: Sadece 5 $ ile portf\u00f6y\u00fcn\u00fcz\u00fc b\u00fcy\u00fck finansal taahh\u00fct olmadan olu\u015fturmaya ba\u015flayabilirsiniz<\/li> <li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: KYC s\u00fcreci, tek bir kimlik belgesi kullan\u0131larak yakla\u015f\u0131k bir dakika s\u00fcrer<\/li> <li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: Kripto paralar, e-c\u00fczdanlar ve geleneksel banka transferleri dahil 100'den fazla y\u00f6ntem<\/li> <\/ul> <p>Bu eri\u015filebilirlik, Pocket Option'u GSK hissesiyle stratejileri test etmek isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in \u00f6zellikle uygun k\u0131lar.<\/p> <h2>\ud83c\udf0d 2025'te GSK: Sa\u011fl\u0131kta Yenilik Lideri<\/h2> <p>GSK, <strong>d\u00fcnyan\u0131n 10. en b\u00fcy\u00fck ila\u00e7 \u015firketi<\/strong> olarak 38,4 milyar $ gelirle y\u0131ll\u0131k %6 b\u00fcy\u00fcme g\u00f6steriyor. Haleon t\u00fcketici sa\u011fl\u0131\u011f\u0131 sat\u0131\u015f\u0131n\u0131 tamamlad\u0131ktan sonra saf biyofarmas\u00f6tik \u015firkete d\u00f6n\u00fc\u015fmeyi ba\u015fard\u0131.<\/p> <p>\u015eirket, solunum hastal\u0131klar\u0131, HIV tedavisi ve a\u015f\u0131lar dahil olmak \u00fczere bir\u00e7ok terap\u00f6tik alanda lider konumda. RSV a\u015f\u0131s\u0131 Arexvy, 2023 onay\u0131ndan bu yana bir blokbaster \u00fcr\u00fcn haline gelerek GSK'n\u0131n y\u00fcksek b\u00fcy\u00fcme pazarlar\u0131nda yenilik yapma yetene\u011fini g\u00f6steriyor.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: GSK'n\u0131n ara\u015ft\u0131rmas\u0131, Rekombinant Zoster A\u015f\u0131s\u0131'n\u0131n (RZV) demans riskini azaltt\u0131\u011f\u0131n\u0131 g\u00f6sterdi - bu da zona \u00f6nlemenin sadece a\u011fr\u0131l\u0131 d\u00f6k\u00fcnt\u00fclerden ka\u00e7\u0131nmak de\u011fil, ayn\u0131 zamanda uzun vadede bili\u015fsel sa\u011fl\u0131\u011f\u0131 korumak anlam\u0131na gelebilece\u011fini ortaya koyuyor!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 GSK Hisse Analizi: Mevcut Performans ve Gelecek G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>20 A\u011fustos 2025 itibar\u0131yla, GSK plc (GSK) NYSE&#8217;de <strong>39,07 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, 2025 boyunca m\u00fckemmel finansal sonu\u00e7lar ve stratejik sat\u0131n almalarla desteklenen \u015firketin g\u00fc\u00e7l\u00fc momentumunu yans\u0131t\u0131yor.<\/p>\n<p><strong>Takviminize not edin: 29 Ekim 2025<\/strong>, GSK yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in kesinlikle kritik bir tarih. \u015eirketin 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu \u00e7eyreklik a\u00e7\u0131klamalar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 GSK Hisselerini Nas\u0131l Etkiler?<\/h3>\n<p>Son tarihleri inceledi\u011fimizde piyasa tepkilerinde net bir desen g\u00f6r\u00fcl\u00fcyor:<\/p>\n<ul>\n<li><strong>30 Temmuz 2025<\/strong>: 2. \u00c7eyrek Kazan\u00e7lar\u0131 &#8211; EPS tahminlerini 0,11 $ a\u015farak hisse senedi sonraki ay %7,64 y\u00fckseldi<\/li>\n<li><strong>29 Nisan 2025<\/strong>: 1. \u00c7eyrek Kazan\u00e7lar\u0131 &#8211; Sa\u011flam performans rehberli\u011fi koruyarak kademeli fiyat art\u0131\u015f\u0131n\u0131 destekledi<\/li>\n<li><strong>\u015eubat 2025<\/strong>: Y\u0131ll\u0131k Sonu\u00e7lar &#8211; Genellikle y\u0131ll\u0131k performans beklentileri i\u00e7in ton belirler<\/li>\n<\/ul>\n<p>Desen a\u00e7\u0131k: pozitif kazan\u00e7 s\u00fcrprizleri an\u0131nda momentum yarat\u0131rken, beklentilerin kar\u015f\u0131lanmas\u0131 istikrarl\u0131 destek sa\u011flar. Yakla\u015fan Ekim raporu, GSK&#8217;n\u0131n y\u00fckseltilmi\u015f rehberli\u011fi g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda \u00f6zellikle \u00f6nemli olabilir.<\/p>\n<h3>6 Ayl\u0131k Fiyat Seyri (\u015eubat-A\u011fustos 2025)<\/h3>\n<p>GSK hisseleri, baz\u0131 dalgalanmalara ra\u011fmen <strong>y\u0131lba\u015f\u0131ndan bu yana %15,46 kazan\u00e7<\/strong> g\u00f6stererek dikkat \u00e7ekici bir diren\u00e7 sergiledi:<\/p>\n<ul>\n<li><strong>\u015eubat 2025<\/strong>: 33,80 $ (tatil sonras\u0131 konsolidasyon)<\/li>\n<li><strong>Nisan 2025<\/strong>: 36,20 $ (1. \u00e7eyrek kazan\u00e7 g\u00fcc\u00fc)<\/li>\n<li><strong>Haziran 2025<\/strong>: 38,40 $ (sat\u0131n alma haberlerinin momentumu)<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: 39,07 $ (mevcut stabilizasyon)<\/li>\n<\/ul>\n<p>Bu y\u00fckseli\u015f e\u011filimi birka\u00e7 \u00f6nemli fakt\u00f6r\u00fc yans\u0131t\u0131yor:<\/p>\n<ul>\n<li>2025&#8217;in ilk yar\u0131s\u0131nda \u00fc\u00e7 b\u00fcy\u00fck FDA onay\u0131<\/li>\n<li>2 milyar dolarl\u0131k efimosfermin alfa sat\u0131n al\u0131m\u0131n\u0131n ba\u015far\u0131s\u0131<\/li>\n<li>\u00d6zel ila\u00e7larda \u00e7ift haneli b\u00fcy\u00fcme<\/li>\n<li>Arexvy liderli\u011finde g\u00fc\u00e7l\u00fc a\u015f\u0131 performans\u0131<\/li>\n<\/ul>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist projeksiyonlar\u0131 ve \u015firket momentumu temelinde beklenenler:<\/p>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: Ortalama hedef 43,13 $ (%9,59 art\u0131\u015f mevcut fiyattan) ve potansiyel en y\u00fcksek 53,63 $<br \/> <strong>2026 Projeksiyonu<\/strong>: Yeni \u00fcr\u00fcnlerin piyasa \u00e7eki\u015fi kazanmas\u0131yla 46-48 $ aral\u0131\u011f\u0131nda devam eden b\u00fcy\u00fcme<br \/> <strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: Ticari ba\u015far\u0131ya ula\u015fan \u00fcr\u00fcnlerle 55-60 $ aral\u0131\u011f\u0131<br \/> <strong>2030 Vizyonu<\/strong>: Ultra uzun etkili HIV tedavileri ve di\u011fer yeniliklerin piyasalar\u0131 domine etmesiyle 65-70 $+ aral\u0131\u011f\u0131<\/p>\n<p><strong>Sonu\u00e7<\/strong>: G\u00dc\u00c7L\u00dc AL &#8211; Mevcut performans, \u00fcr\u00fcn hatt\u0131 g\u00fcc\u00fc ve makul de\u011ferleme kombinasyonu, GSK&#8217;y\u0131 hem k\u0131sa vadeli ticaret hem de uzun vadeli tutma i\u00e7in son derece cazip k\u0131l\u0131yor.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<p><strong>Hukuki Zorluklar<\/strong>: GSK, 2,2 milyar dolarl\u0131k Zantac uzla\u015fmas\u0131 ve Blenrep a\u00e7\u0131klamalar\u0131yla ilgili menkul k\u0131ymet doland\u0131r\u0131c\u0131l\u0131\u011f\u0131 soru\u015fturmas\u0131 dahil devam eden davalarla kar\u015f\u0131 kar\u015f\u0131ya. Bunlar k\u0131sa vadeli volatilite ve potansiyel finansal etkiler yaratabilir.<\/p>\n<p><strong>Reg\u00fclasyon Bask\u0131lar\u0131<\/strong>: Kanser tedavileri i\u00e7in FDA&#8217;n\u0131n g\u00f6z riskleri konusundaki endi\u015feleri ve Blenrep&#8217;in reddi, ila\u00e7 sekt\u00f6r\u00fcndeki s\u00fcrekli d\u00fczenleyici belirsizli\u011fi vurguluyor.<\/p>\n<p><strong>Piyasa Volatilitesi<\/strong>: \u0130\u015flem hacmi son zamanlarda %76,74 artarak 326 milyon hisseye ula\u015ft\u0131, bu da yat\u0131r\u0131mc\u0131lar\u0131n haber ak\u0131\u015f\u0131na kar\u015f\u0131 hassasiyetinin artt\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<p><strong>Finansal G\u00fc\u00e7<\/strong>: 2. \u00e7eyrek EPS 1,23 $ ile tahminleri 0,11 $ a\u015ft\u0131, gelir ise 10,64 milyar $ ile beklentileri dramatik \u015fekilde ge\u00e7ti.<\/p>\n<p><strong>\u00dcr\u00fcn Hatt\u0131 \u0130lerlemesi<\/strong>: Y\u0131l sonuna kadar 4&#8217;\u00fc kritik denemelere giren 16 ge\u00e7 a\u015fama varl\u0131k &#8211; bu inan\u0131lmaz bir gelecekteki gelir potansiyelini temsil ediyor.<\/p>\n<p><strong>Stratejik Sat\u0131n Almalar<\/strong>: Karaci\u011fer hastal\u0131\u011f\u0131 tedavisi i\u00e7in 2 milyar dolarl\u0131k efimosfermin anla\u015fmas\u0131, GSK&#8217;y\u0131 b\u00fcy\u00fcyen metabolik pazarda konumland\u0131r\u0131yor.<\/p>\n<p><strong>FDA Ba\u015far\u0131s\u0131<\/strong>: 2025&#8217;te \u00fc\u00e7 b\u00fcy\u00fck onay al\u0131nd\u0131, iki onay daha bekleniyor &#8211; bu y\u00fcr\u00fctme kabiliyeti etkileyici.<\/p>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<p><strong>Hemen Uygulanacak Plan<\/strong>:<\/p>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> &#8211; Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5&#8217;ini temsil eden bir pozisyonla ba\u015flay\u0131n<\/li>\n<li><strong>29 Ekim kazan\u00e7lar\u0131 i\u00e7in fiyat uyar\u0131lar\u0131 ayarlay\u0131n<\/strong> &#8211; %3-5&#8217;lik herhangi bir d\u00fc\u015f\u00fc\u015fte al\u0131m yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<li><strong>Dolar maliyet ortalamas\u0131 kullan\u0131n<\/strong> &#8211; giri\u015f noktalar\u0131n\u0131 yumu\u015fatmak i\u00e7in haftal\u0131k sabit miktarlarda yat\u0131r\u0131m yap\u0131n<\/li>\n<li><strong>Hukuki geli\u015fmeleri takip edin<\/strong> &#8211; bunlar en b\u00fcy\u00fck k\u0131sa vadeli riski temsil ediyor<\/li>\n<\/ol>\n<p><strong>Esprili t\u00fcccar bilgeli\u011fi<\/strong>: &#8220;GSK ticareti yapmak ila\u00e7 almak gibidir &#8211; bazen a\u015fa\u011f\u0131 inerken tad\u0131 k\u00f6t\u00fc olabilir ama sabah daha iyi hissedersiniz. Panik ataklarda \u015fi\u015feyi kovalamay\u0131n!&#8221;<\/p>\n<h2>\u2705 GSK plc (GSK) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NYSE eri\u015fimi ve makul komisyon oranlar\u0131 sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Genellikle kimlik ve adres kan\u0131t\u0131 gerektirir &#8211; genellikle 1-2 g\u00fcn s\u00fcrer<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon yat\u0131r\u0131n<\/td>\n<td>Risk almaya rahat oldu\u011funuz bir miktarla ba\u015flay\u0131n &#8211; 100 $ bile yolculu\u011funuza ba\u015flaman\u0131z\u0131 sa\u011flar<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;GSK&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>Sadece &#8220;GlaxoSmithKline&#8221; de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Piyasa emirleri yerine limit emirleri kullanarak giri\u015f fiyat\u0131n\u0131z\u0131 kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>\u0130\u015flem \u00f6ncesi miktar, fiyat ve \u00fccretleri \u00e7ift kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Pozisyonunuzu izleyin<\/td>\n<td>Riski y\u00f6netmek i\u00e7in giri\u015f fiyat\u0131n\u0131n %10-15 alt\u0131nda stop-loss ayarlay\u0131n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, piyasaya giri\u015fin eri\u015filebilir olmas\u0131n\u0131 sa\u011flayan birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>En D\u00fc\u015f\u00fck Minimum Para Yat\u0131rma<\/strong>: Sadece 5 $ ile portf\u00f6y\u00fcn\u00fcz\u00fc b\u00fcy\u00fck finansal taahh\u00fct olmadan olu\u015fturmaya ba\u015flayabilirsiniz<\/li>\n<li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: KYC s\u00fcreci, tek bir kimlik belgesi kullan\u0131larak yakla\u015f\u0131k bir dakika s\u00fcrer<\/li>\n<li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: Kripto paralar, e-c\u00fczdanlar ve geleneksel banka transferleri dahil 100&#8217;den fazla y\u00f6ntem<\/li>\n<\/ul>\n<p>Bu eri\u015filebilirlik, Pocket Option&#8217;u GSK hissesiyle stratejileri test etmek isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in \u00f6zellikle uygun k\u0131lar.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te GSK: Sa\u011fl\u0131kta Yenilik Lideri<\/h2>\n<p>GSK, <strong>d\u00fcnyan\u0131n 10. en b\u00fcy\u00fck ila\u00e7 \u015firketi<\/strong> olarak 38,4 milyar $ gelirle y\u0131ll\u0131k %6 b\u00fcy\u00fcme g\u00f6steriyor. Haleon t\u00fcketici sa\u011fl\u0131\u011f\u0131 sat\u0131\u015f\u0131n\u0131 tamamlad\u0131ktan sonra saf biyofarmas\u00f6tik \u015firkete d\u00f6n\u00fc\u015fmeyi ba\u015fard\u0131.<\/p>\n<p>\u015eirket, solunum hastal\u0131klar\u0131, HIV tedavisi ve a\u015f\u0131lar dahil olmak \u00fczere bir\u00e7ok terap\u00f6tik alanda lider konumda. RSV a\u015f\u0131s\u0131 Arexvy, 2023 onay\u0131ndan bu yana bir blokbaster \u00fcr\u00fcn haline gelerek GSK&#8217;n\u0131n y\u00fcksek b\u00fcy\u00fcme pazarlar\u0131nda yenilik yapma yetene\u011fini g\u00f6steriyor.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: GSK&#8217;n\u0131n ara\u015ft\u0131rmas\u0131, Rekombinant Zoster A\u015f\u0131s\u0131&#8217;n\u0131n (RZV) demans riskini azaltt\u0131\u011f\u0131n\u0131 g\u00f6sterdi &#8211; bu da zona \u00f6nlemenin sadece a\u011fr\u0131l\u0131 d\u00f6k\u00fcnt\u00fclerden ka\u00e7\u0131nmak de\u011fil, ayn\u0131 zamanda uzun vadede bili\u015fsel sa\u011fl\u0131\u011f\u0131 korumak anlam\u0131na gelebilece\u011fini ortaya koyuyor!<\/p>\n"},"faq":[{"question":"GSK hisseleri nereden al\u0131nabilir?","answer":"GSK hisseleri, NYSE'de i\u015flem g\u00f6ren bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve ticaret platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"GSK hisseleri almak i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 platforma ba\u011fl\u0131d\u0131r ancak Pocket Option gibi baz\u0131 platformlarda sadece 5 $ ile yat\u0131r\u0131m yapmaya ba\u015flayabilirsiniz."},{"question":"GSK'n\u0131n gelecekteki b\u00fcy\u00fcme potansiyeli nedir?","answer":"Analist projeksiyonlar\u0131na g\u00f6re, GSK'n\u0131n 2025-2030 aras\u0131nda g\u00fc\u00e7l\u00fc b\u00fcy\u00fcme g\u00f6stermesi ve yeni \u00fcr\u00fcnlerle pazar pay\u0131n\u0131 art\u0131rmas\u0131 beklenmektedir."},{"question":"GSK hisseleri al\u0131rken hangi riskler g\u00f6z \u00f6n\u00fcnde bulundurulmal\u0131d\u0131r?","answer":"Hukuki davalar, d\u00fczenleyici belirsizlikler ve piyasa volatilitesi GSK hisseleri i\u00e7in \u00f6nemli riskler aras\u0131nda yer almaktad\u0131r."},{"question":"Yeni ba\u015flayanlar GSK hissesi al\u0131rken nelere dikkat etmelidir?","answer":"K\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131p fiyat uyar\u0131lar\u0131 ayarlamak, dolar maliyet ortalamas\u0131 yapmak ve hukuki geli\u015fmeleri takip etmek yeni ba\u015flayanlar i\u00e7in \u00f6nerilen stratejilerdir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"GSK hisseleri nereden al\u0131nabilir?","answer":"GSK hisseleri, NYSE'de i\u015flem g\u00f6ren bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve ticaret platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"GSK hisseleri almak i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 platforma ba\u011fl\u0131d\u0131r ancak Pocket Option gibi baz\u0131 platformlarda sadece 5 $ ile yat\u0131r\u0131m yapmaya ba\u015flayabilirsiniz."},{"question":"GSK'n\u0131n gelecekteki b\u00fcy\u00fcme potansiyeli nedir?","answer":"Analist projeksiyonlar\u0131na g\u00f6re, GSK'n\u0131n 2025-2030 aras\u0131nda g\u00fc\u00e7l\u00fc b\u00fcy\u00fcme g\u00f6stermesi ve yeni \u00fcr\u00fcnlerle pazar pay\u0131n\u0131 art\u0131rmas\u0131 beklenmektedir."},{"question":"GSK hisseleri al\u0131rken hangi riskler g\u00f6z \u00f6n\u00fcnde bulundurulmal\u0131d\u0131r?","answer":"Hukuki davalar, d\u00fczenleyici belirsizlikler ve piyasa volatilitesi GSK hisseleri i\u00e7in \u00f6nemli riskler aras\u0131nda yer almaktad\u0131r."},{"question":"Yeni ba\u015flayanlar GSK hissesi al\u0131rken nelere dikkat etmelidir?","answer":"K\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131p fiyat uyar\u0131lar\u0131 ayarlamak, dolar maliyet ortalamas\u0131 yapmak ve hukuki geli\u015fmeleri takip etmek yeni ba\u015flayanlar i\u00e7in \u00f6nerilen stratejilerdir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK plc (GSK) Hisseleri Nas\u0131l Al\u0131n\u0131r - GSK plc (GSK) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK plc (GSK) Hisseleri Nas\u0131l Al\u0131n\u0131r - GSK plc (GSK) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T14:36:46+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"GSK plc (GSK) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; GSK plc (GSK) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-20T14:36:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/\",\"name\":\"GSK plc (GSK) Hisseleri Nas\u0131l Al\u0131n\u0131r - GSK plc (GSK) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"datePublished\":\"2025-08-20T14:36:46+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK plc (GSK) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; GSK plc (GSK) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK plc (GSK) Hisseleri Nas\u0131l Al\u0131n\u0131r - GSK plc (GSK) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/","og_locale":"tr_TR","og_type":"article","og_title":"GSK plc (GSK) Hisseleri Nas\u0131l Al\u0131n\u0131r - GSK plc (GSK) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-20T14:36:46+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"GSK plc (GSK) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; GSK plc (GSK) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-20T14:36:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/","name":"GSK plc (GSK) Hisseleri Nas\u0131l Al\u0131n\u0131r - GSK plc (GSK) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","datePublished":"2025-08-20T14:36:46+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-gsk\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"GSK plc (GSK) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; GSK plc (GSK) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":341314,"slug":"how-to-buy-gsk","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu GSK plc (GSK) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu GSK plc (GSK)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-gsk\/"},"pt_AA":{"locale":"pt_AA","id":341315,"slug":"how-to-buy-gsk","post_title":"Como comprar a\u00e7\u00f5es da GSK plc (GSK) - Investimento em a\u00e7\u00f5es da GSK plc (GSK)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-gsk\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/341313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=341313"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/341313\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334054"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=341313"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=341313"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=341313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}